Angela Fleischman, M.D., Ph.D., is particularly excited for improvements in treating early-stage disease.
Angela Fleischman, M.D., Ph.D., of the University of California, Irvine, discusses exciting advancements in the field of myeloproliferative neoplasms (MPNs).
Fleischman, who was honored as one of CURE’s 2018 MPN Heroes, is particularly interested in advancements for early-stage MPNs. If better treatments could be developed in the earlier setting, it could change the national history of the disease, leading to better outcomes.
